Author

C. Schliemann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

L. Angenendt· 2 shared A. Jauch· 1 shared A. K. Ludwig· 1 shared A. Sahal· 1 shared A. Trumpp· 1 shared A. Waclawiczek· 1 shared B. Besenbeck· 1 shared C. Bosc· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

L. Angenendt

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia

S. Beneyto-Calabuig, A. K. Ludwig, J.-A. Kniffka, C. Szu-Tu, C. Rohde, M. Antes, A. Waclawiczek, P. Pervan, M. Janssen, J. J. M. Landry, V. Benes, A. Jauch, M. Brough, M. Bauer, B. Besenbeck, , L. Velten

CloneTracer identifies differentiation routes in AML by adding clonal resolution to single-cell RNA-seq data, revealing disease-defining compartments and therapy response mechanisms.

bioRxiv · Aug 29, 2022Cancer Biology

Adrenomedullin-CALCRL Axis Controls Relapse-Initiating Drug Tolerant Acute Myeloid Leukemia Cells

C. Larrue, N. Guiraud, P.-L. Mouchel, M. Dubois, T. Farge, M. Gotanegre, C. Bosc, E. Saland, M.-L. Travers-Nicolau, M. Sabatier, N. Serhan, A. Sahal, E. Boet, S. Mouche, Q. Heydt, , J.-E. Sarry

The paper identifies the ADM-CALCRL axis as a driver of drug-tolerant AML cells that persist after chemotherapy and proposes it as a therapeutic target to prevent relapse.

bioRxiv · Aug 17, 2020Cancer Biology